Graviton Bioscience

Pleased to share that Dr. Wei Chen, Vice President of Translational medicine at Graviton Bioscience is presenting a poster at Keystone Symposia “Immunometabolism in Tissue Homeostasis and Diseases” starting today.?We demonstrate that selective ROCK2 inhibition concurrently restores metabolic dysfunction and immune homeostasis by directly acting on both adipocytes and immune cells. This work further underscores the unique role ROCK2 is playing in the crosstalk between inflammatory and metabolic signaling pathways. Please stop by the poster if you attend the conference!

We are excited to share that Dr. Samuel D. Waksal, Founder and CEO of Graviton, recently joined Jim Boylan, CEO of Enavate Biosciences, for a Fireside Chat at the?Chardan Corporate Healthcare Masters?on?January 30, 2025.

Traumatic brain injury (TBI) is a leading cause of death and neurological disabilities including impairments in motor function, cognition, sensory function, and mental health. Despite being a prevalent and urgent global unmet clinical need, the TBI long-term consequences incompletely understood and better treatment options are desperately needed. Graviton’s scientists demonstrated for the first time the complex role ROCK2 plays in TBI pathophysiology. The study led by Dr. Vukovic and recently published in journal of “Brain Behavior and Immunity” reported that brain ROCK2 protein levels are robustly and permanently increased by TBI. The treatment with selective ROCK2 inhibitor improves TBI-induced cognitive deficits while directly inhibiting CSF-1-induced microglia proliferation in vitro and preventing microglia repopulation in vivo, which is consistent with known role of ROCK2 in cell division and migration.

Dr. Sam Waksal, Founder and CEO of Graviton Bioscience, will present at the Evercore 7th Annual HealthcareCONx Conference on Wednesday, December 4th, 2024, at 12:55 PM ET. Webcast and replay link: https://lnkd.in/eHf8dtjR

We’re pleased to announce that Graviton's Founder and CEO, Dr. Sam Waksal, will be a speaker and panelist at the China Healthcare Summit in Shanghai, taking place from October 30 to November 1. We look forward to contributing to this global conversation on driving breakthroughs in life sciences and healthcare. #ChinaHealthcareSummit #LifeSciences #Innovation #Healthcare

Graviton is excited to participate in the second annual Life Sciences Day, organized by Life Science Cares, where high school students from across NYC will have the opportunity to explore careers in the life sciences sector. The event will take place from 10 AM to 2 PM across six leading research hubs in the city: Alexandria LaunchLabs, Biolabs@NYU Langone, Cure, SOSV/IndieBio, Taystee Lab Building, and West End Labs. We are thrilled to be part of this initiative to inspire the next generation of life sciences professionals. https://lnkd.in/eHEywtDc

I'm happy to share that Graviton Bioscience's Translational Medicine team is presenting poster titled: "Selective ROCK2 inhibitor ameliorates established dermal and pulmonary fibrosis in murine systemic sclerosis and shifts the balance between Th17 and Treg cells in vivo" at 11th International Conference on Autoimmunity: Mechanisms and Novel Treatments.

We are excited to share a must-watch interview with our amazing CFO Rita Kale, now available on YouTube. In this strong and inspiring conversation, Rita shares her leadership journey as a CFO that is very thoughtful and motivating. Catch the full interview here:?https://lnkd.in/eJmUpwvG Feel fee to share with your network

Rui Wu, PhD, SVP, Head of Research and Preclinical, Chief CMC Officer is presenting on September 30, 2024 at the Cambridge Healthtech Institute's 15th Annual Conference Strategies for Targeting Kinases

We are pleased to share that OV888/GV101 capsule, a potentially first-in-class treatment for cerebral cavernous malformation (CCM), met its Phase 1 study objectives demonstrating a favorable safety and tolerability profile with no serious adverse events.??? 400,000 people worldwide are living with CCM and facing risk of severe bleeds and seizures that can be life-threatening. Ovid and our collaborator Graviton Bioscience believe further development of OV888/GV101 capsule could provide an important opportunity to address the substantial needs of individuals with CCM and look forward to continued engagement with Alliance to Cure Cavernous Malformation, Cavernoma Alliance UK and other community leaders around the world. Ovid and Graviton seek to initiate a Phase 2 proof-of-concept study in 2H 2024. Read the press release to learn more: https://lnkd.in/e4eXikTE